Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.820
-0.058 (-6.61%)
At close: Mar 10, 2025, 4:00 PM
0.875
+0.055 (6.71%)
After-hours: Mar 10, 2025, 8:00 PM EST
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $24.12M in the quarter ending September 30, 2024, a decrease of -0.08%. This brings the company's revenue in the last twelve months to $93.14M, up 5.53% year-over-year. In the year 2023, Nektar Therapeutics had annual revenue of $90.12M, down -2.10%.
Revenue (ttm)
$93.14M
Revenue Growth
+5.53%
P/S Ratio
1.77
Revenue / Employee
$679,832
Employees
137
Market Cap
151.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NKTR News
- 5 days ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 12 days ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - PRNewsWire
- 14 days ago - Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - PRNewsWire
- 14 days ago - Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th - PRNewsWire
- 4 weeks ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 3 months ago - Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting - PRNewsWire
- 4 months ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire